---
title: "Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide. Clinical evidence covers Himalayas-1 and ORIC-944-01. 454 evidence topics quoted from 165 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Rinzimetostat

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

<a id="topic-1.1.1-1"></a>

##### Summary: epidemiology

For all stages of prostate cancer in the United States, an estimated 333,830 new cases are expected in 2026, and an estimated 3,700,086 men were living with prostate cancer in 2023. The age-adjusted incidence rate was 123.2 per 100,000 men per year (2019 to 2023 cases), and 9% of cases are diagnosed at distant stage. From 2014 through 2022 the incidence rate rose by 2.9% per year, by 4.6% per year for regional-stage disease (since 2013), and by 5.6% per year for distant-stage disease (since 2011).

A U.S. model estimated the incidence of metastatic castration-resistant prostate cancer (mCRPC) at 36,100 in 2009 and 42,970 in 2020, with 86% of incidence flowing into mCRPC states from non-metastatic castration-resistant disease. The same model estimated that 97,630 of the men living with prostate cancer in 2009 (4.4%) had metastatic disease, and projected 2020 mCRPC prevalence at 8320 (asymptomatic or minimally symptomatic, before or without progression on chemotherapy), 39,650 (symptomatic, before or without progression on chemotherapy), and 28,720 (progressed on or after first-line chemotherapy). In a review of earlier studies, 10% to 20% of men with prostate cancer developed castration-resistant disease within approximately 5 years of follow-up, and 84% or more had metastases at diagnosis of castration resistance. In Medicare fee-for-service claims, 14,780 men were newly diagnosed with mCRPC between January 2014 and June 2019. ORIC reported an annual U.S. incidence of approximately 17,000 men with mCRPC previously treated with abiraterone; this company estimate is not peer reviewed.

Androgen receptor pathway inhibitor (ARPI) use has moved into castration-sensitive disease. In a U.S. Flatiron cohort of 5361 men with mCRPC (2016 to 2023), 867 (16.2%) had received an ARPI alone before mCRPC diagnosis, a share that rose from 10.3% in 2018 to 34.8% in 2023, and 76.8% received an ARPI as first-line mCRPC treatment. In a U.S. ConcertAI cohort of 609 men (2020 to 2023), 19% had received androgen deprivation therapy (ADT) plus abiraterone and 18% ADT plus another ARPI for metastatic hormone-sensitive disease; 50% and 40% of these, respectively, received an ARPI again as first-line mCRPC treatment. In the Medicare cohort, 10% had received a novel hormonal therapy before mCRPC diagnosis.

Source: [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/); [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html); [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/); [Kirby et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21995694/); [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/); [Raval et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40670254/)

<a id="topic-1.1.1-2"></a>

##### Summary: natural history, survival, and mortality

Prostate cancer deaths are typically the result of progression to mCRPC. An estimated 36,320 U.S. deaths from prostate cancer are expected in 2026, the age-adjusted death rate was 18.9 per 100,000 men per year (2020 to 2024 deaths), and about 1 in 49 men will die of prostate cancer, the second-leading cause of cancer death in U.S. men. The decline in prostate cancer mortality slowed from 3.5% per year during the late 1990s and 2000s to 0.6% per year from 2012 through 2023. A U.S. model attributed 20.5% (2009) and 19.5% (2020) of all-cause deaths among men with prostate cancer to men with mCRPC. Five-year relative survival for distant-stage prostate cancer is 40.1%.

Median overall survival was 24.6 months in the U.S. Flatiron mCRPC cohort, with a trend toward shorter survival after prior ARPI alone or prior ARPI and taxane; 25.6 months from mCRPC diagnosis (95% CI, 25.0 to 26.2) in Medicare fee-for-service claims, where overall mortality was 54%; and 27.2 months in the ConcertAI cohort (20.8 months from first-line therapy). A review of observational studies reported median real-world overall survival of 34 months or less in most studies. In the VISION phase 3 trial, which enrolled participants previously treated with an ARPI and a taxane, median overall survival in the control group was 11.3 months. Among docetaxel-treated trial participants, median overall survival was 13.5 months with liver metastases, 19.4 months with lung metastases, 21.3 months with nonvisceral bone metastases, and 31.6 months with lymph node-only disease. These survival figures come from separate studies with different populations and are cross-study.

Bone metastases were present in 80% or more and visceral metastases in 28% or fewer of cases at mCRPC diagnosis across observational studies; in pooled docetaxel trials, 72.8% of men had bone with or without lymph node metastases, 20.8% visceral disease, and 6.4% lymph node-only disease. In the placebo group of a randomized trial of zoledronic acid, 44.2% of participants had a skeletal-related event, with a median time to first event of 321 days. Among 3,297 SEER-Medicare men with prostate cancer metastatic to bone, 40% had at least one skeletal-related event over a median follow-up of 19 months, which was associated with a higher risk of death (HR, 2.29; 95% CI, 2.09 to 2.51), highest for pathological fracture (HR, 2.77). In U.S. health systems, the cumulative incidence of skeletal-related events after diagnosis of bone metastasis from prostate cancer was 21.5% at 6 months, 30.4% at 12 months, and 41.9% at 24 months.

Source: [AUA (2026)](https://www.auanet.org/guidelines-and-quality/guidelines/advanced-prostate-cancer); [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/); [National Cancer Institute SEER Cancer Stat Facts](https://seer.cancer.gov/statfacts/html/prost.html); [American Cancer Society (2026)](https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html); [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/); [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/); [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/); [Raval et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40670254/); [Raval et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41266184/); [Sartor et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8446332/); [Halabi et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4872320/); [Saad et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12359855/); [McDougall et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4786354/); [Oster et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23884473/)

<a id="topic-1.1.1-3"></a>

##### Summary: disease biology and resistance to androgen receptor pathway inhibitors

Castration-resistant prostate cancer continues to rely on androgen receptor (AR) signaling. In metastatic biopsies, 107 of 150 cases (71.3%) harbored AR pathway aberrations and at least 34 of 150 (22.7%) had alterations in DNA repair or recombination genes. Approximately 20% to 40% of men with mCRPC have no PSA response to enzalutamide or abiraterone, and “virtually all” initial responders acquire secondary resistance. In men with AR splice variant 7, PSA response rates were 0% with enzalutamide and with abiraterone, compared with 53% and 68% in men without it. Described resistance mechanisms fall into restored AR signaling, AR bypass signaling, and complete AR independence, including relapse with neuroendocrine features and low or absent AR expression. EZH2, the enzymatic component of polycomb repressive complex 2 (PRC2), was expressed at 2-fold higher levels in castration-resistant neuroendocrine than adenocarcinoma tumors, acts as a co-activator of the AR in castration-resistant cells, and in preclinical models EZH2 inhibitors restored AR expression and sensitivity to antiandrogen therapy.

Source: [Antonarakis et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4201502/); [Watson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4771416/); [Robinson et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4484602/); [Beltran et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4777652/); [Ku et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5367887/); [Xu et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3625962/)

<a id="topic-1.1.1-4"></a>

##### Summary: humanistic burden

In a survey of 221 men with mCRPC and 159 caregivers in seven countries, mCRPC affected mood, emotional and mental health (50% to 77%), sleep (48% to 68%), career goals (48% to 80%), and social activities (46% to 65%); patients reported taking 7 to 12 pills per day, 52% to 73% devoted 9 hours or more per week to mCRPC care, and one in three reported persistent fatigue. Caregivers provided an average of 11 hours of care per week; 53% reported an effect on their ability to work, and among the 79% who worked outside the home before diagnosis, 40% reduced their hours and 13% stopped working. In a real-world cohort of 151 men (873 questionnaires), the mean EQ visual analog score at inclusion was 73.2 of 100, fatigue, pain, and insomnia were the most impaired domains, and these deteriorated in more than 50% of men.

Health state utility values elicited with the EQ-5D-5L from 163 men with metastatic castration-resistant disease ranged from 0.830 (asymptomatic or mildly symptomatic before chemotherapy) to 0.625 (symptomatic before chemotherapy). A meta-analysis estimated pooled mean baseline EQ-5D index values of 0.79 (95% CI, 0.70 to 0.84) in first-line treatment (7 studies) and 0.69 (95% CI, 0.67 to 0.71) in second-line or later treatment (4 studies), and EQ VAS scores of 74.63 and 65.82, respectively.

In the ARPI change group of the PSMAfore trial, which enrolled participants after progression on one ARPI, median time to worsening was 4.27 months for FACT-P total score, 3.88 months for EQ-5D-5L utility, and 3.65 months for BPI-SF pain intensity, and median time to first symptomatic skeletal event was 17.97 months. In the CARD trial, after docetaxel and one ARPI, a pain response occurred in 21 of 109 participants (19%) receiving abiraterone or enzalutamide, with a median time to pain progression of 8.5 months.

Among 281 patients in a financial toxicity study, 79 reported high financial toxicity, and those patients more often used savings to pay for treatment (62% vs 17%). Among 4,153 Medicare Part D patients filling abiraterone or enzalutamide, the median monthly out-of-pocket payment was $706 (range, $0 to $3,505) and mean adherence was 75%.

Source: [Jain et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12218467/); [Kuppen et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31883940/); [Lloyd et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/26686802/); [Castro et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12311294/); [Fizazi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40441170/); [Fizazi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32926841/); [Joyce et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37416955/); [Caram et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7959094/)

<a id="topic-1.1.1-5"></a>

##### Summary: economic burden and healthcare resource utilization

Among 296 U.S. patients progressing from metastatic castration-sensitive to castration-resistant disease, mean all-cause healthcare costs per patient per month (PPPM) increased from $4,424 to $9,717 and prostate cancer-related costs from $2,859 to $8,012. In 459 commercially, Medicare Advantage-, and Medicaid-insured patients, mean total costs during first-line mCRPC therapy (average duration 8.5 months) were $13,746 all-cause and $12,061 prostate cancer-related PPPM. In Medicare fee-for-service claims, 11,528 of 14,780 men (78%) received life-prolonging therapy after mCRPC diagnosis, 6275 initiated second-line, and 2945 third-line therapy; mean all-cause medical and pharmacy costs per patient per year (2019 USD) were $27,468 in the year before diagnosis, $148,325 in first line, $160,118 in second line, and $165,186 in third line, and outpatient days per patient per year rose from 10.4 before diagnosis to 22.0 in third line. In 4758 older Medicare beneficiaries receiving first-line treatment, mean all-cause costs were $111,060 per patient per year.

Among 923 Medicare patients treated after one ARPI, 714 received a second ARPI and 209 a taxane; median overall survival was approximately 1 year in both cohorts, and serious adverse events were more frequent with a taxane (66.0% vs 42.2%). Across two U.S. data sources, 22% and 13% of taxane-treated patients received more than 8 cycles. Over 6 months of first-line treatment in employer-sponsored insurance (4,298 patients), mean gross drug payments ranged from $12,804 for docetaxel to $115,525 for sipuleucel-T. The attributable Medicare cost of at least one skeletal-related event was $21,191 (2013 USD), and hospitalizations were nearly four times as frequent among men with such an event.

Genomic testing adds cost and is applied unevenly: 674 of 5213 U.S. patients with mCRPC (13%) had a documented genetic test before PARP inhibitor approval, the biomarker testing rate in metastatic prostate cancer in a U.S. community oncology network was 34%, and tissue sequencing results were available for 72 of 150 enrolled patients in one study. A U.S. model included a next-generation sequencing cost of $5,800, and a U.S. model valued a PSMA PET scan at $6,036.17 to $6,336.17 (2021 USD), depending on the tracer.

Source: [Kaye et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11217864/); [Kaye et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/38204397/); [Freedland et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10500004/); [Swami et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37248148/); [McKay et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42836510/); [Shore et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13401553/); [Kaye et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10113111/); [McDougall et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4786354/); [Shore et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33906368/); [Mahmud et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13348720/); [Shevrin et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42161163/); [Su et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7870786/); [Yee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10811023/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Rinzimetostat Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary: development status, pharmacology, dose selection, and Himalayas-1 phase 3 design

- Rinzimetostat (ORIC-944) is an investigational oral allosteric inhibitor of polycomb repressive complex 2 (PRC2) that binds the embryonic ectoderm development (EED) subunit, which prevents methylation of histone 3 at lysine 27 and depletes H3K27 trimethylation (H3K27me3). ORIC Pharmaceuticals has “not submitted for, or obtained, regulatory approval for any product candidate”. ORIC filed and cleared an investigational new drug application with the FDA in the fourth quarter of 2021 and holds a worldwide, exclusive license from Mirati entered on August 3, 2020.
- In single-agent dosing, ORIC reported, as of December 10, 2023, an approximate 20-hour clinical half-life, no signs of cytochrome P450 autoinduction, and a maximal decrease (≥75%) in H3K27me3 in peripheral blood monocytes at doses as low as 200 mg once daily. ORIC reported that pharmacokinetic and pharmacodynamic data were “highly consistent as a single agent and in combination with darolutamide”, and that in the food-effect cohort “there does not appear to be a significant food effect”.
- After dose exploration, ORIC selected provisional doses of 400 mg and 600 mg once daily with darolutamide 600 mg twice daily, and 600 mg, 800 mg, and 1,200 mg once daily with apalutamide 240 mg once daily. In dose optimization, 18 participants received 400 mg and 15 received 600 mg once daily with darolutamide. ORIC’s exposure-response analysis across 113 participants (single-agent and combination) found no correlation between exposure and radiographic progression-free survival (rPFS), PSA reduction, ctDNA reduction, or H3K27me3 changes, and significant correlations with grade 2 or higher, grade 3 or higher, and serious adverse events, gastrointestinal and hematologic adverse events, and treatment modifications. ORIC selected 400 mg once daily with darolutamide as the recommended phase 3 dose (RP3D), in accordance with the FDA’s Project Optimus initiative. Rinzimetostat is taken orally once daily on a continuous schedule in 28-day cycles, and with or without food in Himalayas-1.
- Himalayas-1 (NCT07723248; protocol ORIC-944-05) is a randomized, open-label, global, multicenter phase 3 trial whose protocol ORIC finalized after End-of-Phase 1 interactions with the FDA and other health authorities. ORIC announced its initiation in July 2026; the registry lists an actual start of 2026-08-03, status “Recruiting”, estimated primary completion in 2028-03, and estimated study completion in 2030-09. ORIC sponsors the trial, and Bayer supplies darolutamide under an agreement dated July 7, 2026.
- Approximately 600 participants with mCRPC whose disease progressed on abiraterone given for ≥12 weeks in the mCSPC or first-line mCRPC setting, with ECOG performance status 0 or 1, are randomized 1:1 to rinzimetostat 400 mg once daily plus darolutamide 600 mg twice daily or to a prespecified physician’s choice of control: an androgen receptor pathway inhibitor (ARPI), with a second 1:1 randomization to darolutamide 600 mg twice daily or enzalutamide 160 mg once daily, or docetaxel 75 mg/m2 intravenously every 21 days for up to 10 cycles. Randomization is stratified by prior docetaxel in the mCSPC setting, control category (ARPI or docetaxel), and hepatic metastases. Prior ARPIs other than abiraterone and other prior systemic anticancer therapy are excluded, except docetaxel for mCSPC. The trial is planned across approximately 250 sites in 25 countries.
- The primary endpoint is rPFS by blinded independent central review (BICR), per RECIST 1.1 for soft tissue and PCWG3 for bone, or death. Overall survival is the key secondary endpoint and will be formally tested only if the primary rPFS analysis is statistically significant. Other secondary endpoints include objective response rate, duration of response, PSA50 and PSA90 response, time to PSA progression, time to first symptomatic skeletal event, adverse events, pharmacokinetics, and patient-reported outcomes (BPI-SF, FACT-P, EQ-5D-5L, and PRO-CTCAE). ORIC expects its cash runway to extend into the second half of 2028, beyond the anticipated primary endpoint readout.

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm); [ORIC Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526064005/oric-20251231.htm); [National Cancer Institute Thesaurus](https://api-evsrest.nci.nih.gov/api/v1/concept/ncit/C188381?include=full); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421); [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/); [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248); [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf); [ORIC Pharmaceuticals second quarter results (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-second-quarter-2026-financial-results-and-operational-updates/)

<a id="topic-1.1.2-2"></a>

##### Summary: ORIC-944-01 efficacy by cohort and data cutoff (company-reported)

ORIC-944-01 (NCT05413421) is a first-in-human, open-label, multicenter phase 1/1b study of rinzimetostat as a single agent (Part I), in combination with an ARPI (Part II), and in combination dose optimization (Part III). ORIC reported all results below in press releases, investor presentations, and SEC filings; no Himalayas-1 results are available.

- Apalutamide combination dose escalation, 600 mg and 800 mg (December 10, 2024 cutoff; 6 participants): 3 of 6 participants achieved confirmed PSA50 responses, of whom 2 achieved confirmed PSA90 responses; all PSA responses were maintained for ≥12 weeks, including a confirmed PSA90 response ongoing at 38 weeks.
- Combination dose exploration, 400 mg to 800 mg with apalutamide or darolutamide (PSA data as of May 9, 2025; 17 participants with a median of three prior lines, including abiraterone): PSA50 response in 10 of 17 (59%), confirmed in 8 of 17 (47%), with one additional response pending confirmation; PSA90 response in 4 of 17 (24%), all confirmed. ORIC reported PSA responses at all dose levels and at comparable rates with each partner.
- Combination dose exploration, 400 mg to 1,200 mg with apalutamide or darolutamide (September 2025 cutoff; 20 participants, including the 17 reported in May 2025; 100% with prior abiraterone and 35% with prior docetaxel): PSA50 response in 11 of 20 (55%) unconfirmed and 8 of 20 (40%) confirmed; PSA90 response in 4 of 20 (20%), all confirmed. Among 17 participants with ctDNA samples and evidence of ctDNA at baseline, assessed at cycle 2 day 1, 13 (76%) had a ctDNA reduction greater than 50% and 10 (59%) changed from detected ctDNA (≥0.5%) to non-detected ctDNA (<0.5%); ctDNA remained detected in 5 of 17 (29%) and remained non-detected in 2 of 17 (12%).
- Darolutamide dose optimization, 400 mg, post-abiraterone cohort (18 participants treated; median two prior lines, 39% with prior docetaxel): as of March 6, 2026, in 18 efficacy-evaluable participants with a median follow-up of 4.9 months, landmark rPFS rates were 93% at 3 months, 84% at 4 months, and 84% at 5 months; ORIC lists median rPFS as “Not mature”. At the January 16, 2026 clinical cutoff, among 15 participants with at least one post-baseline PSA assessment, PSA50 response occurred in 7 of 15 (47%), confirmed in 5 of 15 (33%), and PSA90 response in 2 of 15 (13%), confirmed in 1 of 15 (7%). Among 14 participants with detectable ctDNA at baseline (data on file as of March 11, 2026), a 50% molecular response (MR50) occurred in 10 of 14 (71%) and a 90% molecular response (MR90) in 4 of 14 (29%), across AR-mutated, AR-amplified, and AR wildtype genotypes.
- Darolutamide dose optimization, 600 mg, post-abiraterone cohort (15 participants treated): no cohort-level efficacy figures are reported; ORIC stated that its exposure-response analysis showed that 400 mg and 600 mg once daily “provided comparable efficacy”.
- Post-androgen receptor inhibitor cohort, 400 mg with darolutamide (March 6, 2026 cutoff; 19 participants with mCRPC previously treated with AR inhibitors): landmark rPFS rates were 93% at 3 months, 85% at 4 months, and 85% at 5 months, with a median follow-up of 4.8 months.
- Food-effect cohort, 400 mg fed with darolutamide (March 6, 2026 cutoff): two confirmed PSA50 responses and one confirmed PSA90 response occurred in the first five participants dosed.

Source: [ClinicalTrials.gov NCT05413421](https://clinicaltrials.gov/study/NCT05413421); [ORIC Pharmaceuticals early combination data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-provides-early-phase-1b-combination-data-for-oric-944-operational-highlights-for-2024-and-anticipated-upcoming-milestones/); [ORIC Pharmaceuticals preliminary phase 1b data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-data-from-ongoing-phase-1b-trial-of-oric-944-in-combination-with-ar-inhibitors-for-the-treatment-of-patie/); [ORIC Pharmaceuticals dose exploration completion release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-completion-of-dose-exploration-portion-of-oric-944-phase-1b-clinical-trial-and-continues-to-demonstrate-potential-best-in-class-efficacy-and-safety/); [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-1.1.2-3"></a>

##### Summary: ORIC-944-01 safety by cohort and data cutoff (company-reported)

- Single agent (December 10, 2023 cutoff): ORIC reported only grade 1 and 2 treatment-related adverse events (TRAEs) at dose levels corresponding with strong target engagement.
- Single-agent dose escalation, 100 mg to 900 mg (December 10, 2024 cutoff; 25 participants): TRAEs in ≥10% of participants were diarrhea in 10 (40%), fatigue in 8 (32%), decreased appetite in 8 (32%), nausea in 7 (28%), anemia in 5 (20%; grade 3 in 3 [12%]), platelet count decreased in 5 (20%; grade 3 in 2 [8%]), white blood cell count decreased in 3 (12%; grade 3 in 1 [4%]), and blood creatinine increased, dizziness, and vomiting in 3 (12%) each. At 900 mg (6 participants), grade 3 anemia and grade 3 platelet count decrease each occurred in 2 (33%). No grade 4 or 5 events were reported.
- Apalutamide combination dose escalation, 600 mg and 800 mg (December 10, 2024 cutoff; 6 participants): TRAEs were primarily grade 1 and 2, with one grade 3 TRAE of fatigue; the first two dose levels cleared without dose-limiting toxicities or treatment discontinuations related to safety.
- Combination dose exploration, 400 mg to 800 mg (April 22, 2025 cutoff; 17 participants): diarrhea, the most common TRAE, occurred in 9 of 17 (53%), with one grade 3 event; no grade 4 or 5 TRAEs were attributed to rinzimetostat with apalutamide or darolutamide.
- Combination dose exploration, 400 mg to 1,200 mg (September 2025 cutoff; 20 participants: 3 at 400 mg, 9 at 600 mg, 5 at 800 mg, 3 at 1,200 mg): treatment-emergent adverse events attributed to study treatment were diarrhea (grade 1 to 2 in 11 [55%] and grade 3 in 1 [5%]), fatigue in 9 (45%), nausea in 7 (35%), dysgeusia in 5 (25%), vomiting and hypothyroidism in 4 (20%) each, and constipation and blood creatinine increased in 3 (15%) each. No grade 4 or 5 events were attributed to study treatment. One participant discontinued for a TRAE of grade 1 diarrhea and grade 2 nausea.
- Darolutamide dose optimization, post-abiraterone cohorts (January 2026 cutoff): with 400 mg (18 participants), fatigue occurred in 7 (39%), diarrhea in 4 (22%), nausea in 4 (22%), blood creatinine increased in 3 (17%), and decreased appetite and anemia in 2 (11%) each; grade ≥3 TRAEs occurred in 6% (a single grade 3 TRAE), there were no serious TRAEs, and no grade 4 or 5 events were attributed to rinzimetostat or darolutamide. Dose interruptions occurred in 6%, dose reductions in none, and discontinuations in 6%. With 600 mg (15 participants), fatigue occurred in 6 (40%), diarrhea in 5 (33%), nausea in 4 (27%), blood creatinine increased and anemia in 2 (13%) each, and decreased appetite in 1 (7%); dose interruptions occurred in 13%, dose reductions in 7%, and discontinuations in 13%.
- Darolutamide dose optimization, post-ARPI safety set including the post-abiraterone participants (January 2026 cutoff; 72 participants): with 400 mg (37 participants), fatigue occurred in 10 (27%), diarrhea and nausea in 7 (19%) each, blood creatinine increased in 6 (16%; grade 3 in 1 [3%]), decreased appetite in 5 (14%), and anemia in 4 (11%), with “8% Grade 3”; dose interruptions occurred in 11%, reductions in 3%, and discontinuations in 3%. With 600 mg (35 participants), diarrhea occurred in 13 (37%), fatigue, nausea, and blood creatinine increased in 8 (23%) each, anemia in 6 (17%; grade 3 in 1 [3%]), and decreased appetite in 5 (14%), with “11% Grade 3”; dose interruptions occurred in 17%, reductions in 9%, and discontinuations in 11%. One grade 4 acute kidney injury was reported in this safety set.
- Food-effect cohort, 400 mg fed (March 6, 2026 cutoff; first five participants): all TRAEs were grade 1 except a single grade 2 TRAE.

Source: [ORIC Pharmaceuticals initial phase 1b data release (2024)](https://oricpharma.com/news/oric-pharmaceuticals-provides-initial-phase-1b-data-for-oric-944-operational-highlights-for-2023-and-anticipated-upcoming-milestones/); [ORIC Pharmaceuticals January presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525005028/d908680dex991.htm); [ORIC Pharmaceuticals early combination data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-provides-early-phase-1b-combination-data-for-oric-944-operational-highlights-for-2024-and-anticipated-upcoming-milestones/); [ORIC Pharmaceuticals preliminary phase 1b data release (2025)](https://oricpharma.com/news/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-data-from-ongoing-phase-1b-trial-of-oric-944-in-combination-with-ar-inhibitors-for-the-treatment-of-patie/); [ORIC Pharmaceuticals November presentation (2025)](https://www.sec.gov/Archives/edgar/data/1796280/000119312525280247/d898404dex991.htm); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-1.1.2-4"></a>

##### Summary: other PRC2 and EZH2 inhibitors in mCRPC (cross-trial context)

The trials below combined a PRC2 or EZH2 inhibitor with enzalutamide or abiraterone and enrolled populations with follow-up durations that differ from those of ORIC-944-01; every comparison with rinzimetostat is cross-trial.

- Mevrometostat plus enzalutamide, randomized phase 1 dose expansion after abiraterone (September 2, 2024 cutoff; 81 participants; mevrometostat 1250 mg twice daily fasted plus enzalutamide, n=41, or enzalutamide, n=40; median follow-up 9.6 months): median rPFS was 14.3 months with the combination and 6.2 months with enzalutamide (hazard ratio 0.51; 90% CI 0.28 to 0.95), and confirmed PSA50 response occurred in 34.1% and 15.4%. Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 53.7% and 42.5%, and diarrhea in 78.0% with the combination; there were no treatment-related deaths.
- Mevrometostat 875 mg twice daily with food plus enzalutamide: as of November 15, 2024, among 29 participants, serious mevrometostat-related TEAEs occurred in 3 (10.3%), all grade 3, and TEAEs led to withdrawal of mevrometostat in 4 (13.8%); this dose was selected for phase 3. As of September 1, 2025, in cohort 2C (14 participants with prior abiraterone, enzalutamide naive), median rPFS was not estimable (90% CI 6.2 to not estimable) and confirmed PSA50 response occurred in 6 (42.9%); in cohorts 2A and 2C combined, grade ≥3 TEAEs occurred in 41.3% and grade ≥3 mevrometostat-related TEAEs in 31.0%.
- Mevrometostat phase 3: MEVPRO-1 (NCT06551324) is an open-label trial of mevrometostat plus enzalutamide versus physician’s choice of enzalutamide or docetaxel after ≥12 weeks of abiraterone, stratified by prior docetaxel in mCSPC, physician’s choice of comparator, and hepatic metastases, with rPFS by BICR as the primary endpoint and overall survival as a key secondary endpoint; its registry status is “Active, not recruiting”, with a listed date of 2027-02-28. MEVPRO-2 (NCT06629779) enrolls treatment-naive mCRPC, and MEVPRO-3 (NCT07028853) enrolls ARPI-naive mCSPC.
- Tazemetostat plus enzalutamide, CELLO-1 randomized phase 2 after abiraterone (41 and 40 participants analyzed): median rPFS was 22.1 months (95% CI 16.6 to 27.6) with the combination and 11.1 months (95% CI 5.7 to 16.5) with enzalutamide, and confirmed PSA50 response occurred in 19.5% and 15.0%. The study was terminated early when the sponsor discontinued tazemetostat development in mCRPC, and the primary endpoint was not met. Tazverik (tazemetostat) was voluntarily withdrawn from the U.S. market because of an increased rate of hematologic second primary malignancies: as of March 6, 2026, 18 of 318 (5.7%) participants treated with tazemetostat in a study developed them, compared with no reported events in the control arm.
- Class safety: a 2026 review states that no comparable secondary-malignancy signal has been publicly reported for mevrometostat, valemetostat, or tulmimetostat, calling this “reassuring but not yet definitive”, and notes that the median follow-up of approximately 9.6 months in the phase 1/2 mevrometostat experience is shorter than the interval over which therapy-related MDS/AML typically emerge. ORIC reported that no hematologic tumorigenesis was observed in a 13-week rat GLP toxicology study of rinzimetostat, in contrast to tazemetostat.
- CPI-1205 plus enzalutamide (ProSTAR phase 1b/2): composite response rate was 31.4% with the combination and 17.1% with enzalutamide, and best objective response rate 7.89% and 5.71%. ORIC lists CPI-1205 and tazemetostat as “Discontinued” and mevrometostat as in ongoing phase 3 trials.
- ORIC benchmark comparison (March 2026 presentation): ORIC set rinzimetostat 400 mg plus darolutamide (n=18; median follow-up 4.9 months; landmark rPFS 93%, 84%, and 84% at 3, 4, and 5 months; grade ≥3 treatment-related adverse events [TRAEs] 6%; no serious TRAEs) beside mevrometostat 875 mg fed plus enzalutamide (n=14; 9.2 months; 92%, 92%, and 84%; grade ≥3 TRAEs 36%; serious TRAEs 21%), mevrometostat 1250 mg fasted plus enzalutamide (n=41; 11.7 months; 92%, 86%, and 80%; 49%; 24%), and enzalutamide (n=40; 9.0 months; 78%, 70%, and 60%; grade ≥3 TRAEs 23%). Dose reductions were none, 7%, and 37%, and discontinuations 6%, 7%, and 2%, for rinzimetostat, mevrometostat fed, and mevrometostat fasted. ORIC states that competitor rPFS percentages were “estimated from published data” and labels the table a “Cross-trial comparison in previously treated mCRPC patients”.

Source: [Schweizer et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.LBA138); [Matsubara et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.5046); [Matsubara et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.7_suppl.195); [Shore et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13203012/); [ClinicalTrials.gov NCT06551324](https://clinicaltrials.gov/study/NCT06551324); [ClinicalTrials.gov NCT07028853](https://clinicaltrials.gov/study/NCT07028853); [ClinicalTrials.gov NCT04179864](https://clinicaltrials.gov/study/NCT04179864); [ClinicalTrials.gov NCT04179864 results](https://clinicaltrials.gov/study/NCT04179864?tab=results); [FDA Tazverik safety alert (2026)](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-alerts-health-care-providers-and-patients-about-increased-risk-new-blood-cancers-tazverik); [Alumkal and Ellis (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13552191/); [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/); [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf); [ClinicalTrials.gov NCT03480646 results](https://clinicaltrials.gov/study/NCT03480646?tab=results); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Rinzimetostat

<a id="topic-1.1.3-1"></a>

##### Summary: price status of rinzimetostat and darolutamide

- Rinzimetostat is investigational. ORIC states that it has “not submitted for, or obtained, regulatory approval for any product candidate” and has “no products approved for commercial sale”. The Himalayas-1 phase 3 trial (NCT07723248) of rinzimetostat 400 mg once daily with darolutamide 600 mg twice daily is recruiting, with an actual start date of 3 August 2026 and an estimated primary completion date of March 2028.
- No wholesale acquisition cost, average sales price, brand name, or unit strength of rinzimetostat was identified. ORIC describes post-abiraterone mCRPC as “a $3.5bn total addressable market annually in the US”, and its presentation notes that the figure “assumes current price of ARPIs for illustrative purposes”.
- Darolutamide (Nubeqa, Bayer) is supplied as 300 mg tablets in bottles of 120 tablets. A filing with the California Department of Health Care Access and Information reports a wholesale acquisition cost of $15,100.80 for the 120-tablet bottle (NDC 50419039501), effective 1 January 2026, after an increase of $847.20.
- The labeled darolutamide dose is 600 mg orally twice daily with food, with a concurrent GnRH agonist or antagonist or prior bilateral orchiectomy; for grade 3 or higher or intolerable adverse reactions the dose is withheld or reduced to 300 mg twice daily. Its labeled indications are nmCRPC and mCSPC (alone or in combination with docetaxel); mCRPC is not a labeled indication.
- For Himalayas-1, Bayer provides darolutamide “at no cost for use in the trial in combination with rinzimetostat”, and ORIC retains global development and commercial rights to rinzimetostat.

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm); [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248); [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf); [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22manufacturer_name%22%2C%22ndc%22%2C%22drug_prod_desc%22%2C%22wac_effective_date%22%2C%22wac_increase_amount%22%2C%22wac_after_increase%22%20FROM%20%22dda8a083-bc81-4f6d-b02f-935a2df70328%22%20WHERE%20%22drug_prod_desc%22%20LIKE%20%27Nubeqa%25%27); [ORIC Pharmaceuticals Himalayas-1 initiation release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-evaluating-rinzimetostat-in-combination-with-nubeqa-darolutamide-supported-by-clinical-collaboration-with/)

<a id="topic-1.1.3-2"></a>

##### Summary: comparator prices and costs of care

- The physician's choice control arm of Himalayas-1 comprises darolutamide 600 mg twice daily, enzalutamide 160 mg once daily, or docetaxel 75 mg/m2 intravenously every 21 days for up to 10 cycles.
- Enzalutamide (Xtandi): the Medicare negotiated price effective 1 January 2027 is $7,004 per 30-day supply, 48% below the calendar year 2024 list price (wholesale acquisition cost) of $13,480.
- Medicare Part B payment limits for 1 October to 31 December 2026, based on second-quarter 2026 ASP data: docetaxel $0.471 per mg; cabazitaxel $231.688 per mg; sipuleucel-T $55,663.131 per infusion; pembrolizumab $62.253 per mg; denosumab $29.856 per mg; zoledronic acid $17.673 per mg. The file lists no payment limit for radium-223 dichloride (“N/A”) and notes $212.84 per microCurie at 100% of AWP and $177.37 per microCurie at 100% of WAC.
- Hospital outpatient payment rates for October 2026 are $180.422 for radium-223 dichloride (A9606, APC 1745) and $266.541 for lutetium Lu 177 vipivotide tetraxetan (A9607, APC 9054).
- Lutetium Lu 177 vipivotide tetraxetan has no ASP-based benchmark. Authors employed by Sanofi, the manufacturer of cabazitaxel, estimated a per-dose cost of $55,522 from the median Medicare Administrative Contractor payment rate, assuming a 200-mCi dose. A published U.S. model used per-cycle costs of $32,062 for lutetium Lu 177 vipivotide tetraxetan, based on the price of 177Lu-DOTATATE as a proxy, and $14,382 for cabazitaxel.
- Costs of care in a cohort of 14,780 men with mCRPC (2019 USD): mean all-cause medical and pharmacy costs per patient per year were $27,468 in the year before mCRPC diagnosis, $148,325 during first-line, $160,118 during second-line, and $165,186 during third-line therapy. In 296 patients progressing from mCSPC to mCRPC, mean all-cause total costs per patient per month increased from $4,424 to $9,717.

Source: [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248); [CMS negotiated prices fact sheet (2025)](https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf); [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip); [CMS OPPS Addendum B (2026)](https://www.cms.gov/files/zip/October-2026-OPPS-Addendum-B.zip); [Flannery et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724722/); [Gogebakan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13224915/); [Freedland et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10500004/); [Kaye et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11217864/)

<a id="topic-1.1.3-3"></a>

##### Summary: eligible population inputs

- ORIC estimates that “the annual incidence of mCRPC patients previously treated with abiraterone is approximately 17,000” in the U.S., and states that abiraterone has maintained “>50% market share of new prescriptions over the last five years”. These are company-reported figures. No peer-reviewed estimate of the U.S. annual number of men with mCRPC previously treated with abiraterone was identified.
- A U.S. model estimated mCRPC incidence of 36,100 in 2009 and 42,970 in 2020, with 86% of incident mCRPC arising from the nmCRPC clinical state.
- In a real-world cohort of 5,361 patients, 867 (16.2%) had received an ARPI alone and 83 (1.5%) an ARPI and a taxane before mCRPC diagnosis; ARPI-only treatment before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023, and 76.8% of patients received an ARPI as first-line mCRPC treatment.
- Among 14,780 men newly diagnosed with mCRPC in Medicare fee-for-service claims (January 2014 to June 2019), 78% received at least one line of therapy, 42% at least two, and 20% at least three. Abiraterone accounted for 36% of first-line, 28% of second-line, and 17% of third-line therapy; enzalutamide for 28%, 33%, and 19%; and docetaxel for 16%, 15%, and 24%.

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm); [Scher et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4603789/); [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/); [Freedland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11096091/)

<a id="topic-1.1.3-4"></a>

##### Summary: published comparator models

- No budget impact model or cost-effectiveness analysis of rinzimetostat was identified.
- A U.S. payer budget impact model of darolutamide in nmCRPC for a hypothetical 1-million-member plan over 5 years estimated approximately 90 incident nmCRPC cases each year and 332 treatment-eligible cases by year 5; introducing darolutamide along with other targeted therapies increased the budget by $158,640 ($0.0132 PMPM) in year 1 and saved $149,240 ($0.0124 PMPM) by year 5.
- A U.S. budget impact analysis of hospitalization costs with darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer, over a 5-year horizon, reported a cumulative budget impact of -$9.71 per treated member per month.
- A U.S. health care partitioned survival model of lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel (60-month horizon) estimated an incremental cost of $36,258, an incremental gain of 0.10 QALYs, and an ICER of $358,990 per QALY gained. Authors employed by Sanofi state that the model used the price of 177Lu-DOTATATE as a proxy and that “the magnitude of difference is likely greater than reported”.
- A U.S. payer model of third-line cabazitaxel versus a second androgen receptor-targeted agent (18-month horizon) estimated $323,095 (17%) in avoided total costs, 58 fewer hospitalization days, and 2 fewer ICU days.
- A U.S. payer model of genomic test-directed olaparib after a new hormonal agent estimated an ICER of $116,903 per QALY in one scenario and cost savings of $1,980 in the other.

Source: [Appukkuttan et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10394191/); [Morgans et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11365817/); [Gogebakan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13224915/); [Flannery et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13724722/); [Morgans et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9284907/); [Su et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7870786/)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary: conclusions for formulary review

- Rinzimetostat (ORIC-944) is an investigational oral allosteric inhibitor of PRC2 that binds the EED subunit. ORIC states that it has “not submitted for, or obtained, regulatory approval for any product candidate”, and no source states a submission or launch timing. No brand name, dosage strength, wholesale acquisition cost, or average sales price has been published.
- The population is men with mCRPC whose disease progressed on abiraterone. ORIC estimates an annual U.S. incidence of approximately 17,000 men in this population; no peer-reviewed estimate of this number was identified. ARPI use before mCRPC diagnosis rose from 10.3% in 2018 to 34.8% in 2023 in a U.S. cohort of 5,361 men, and median overall survival in U.S. real-world mCRPC cohorts ranged from 24.6 to 27.2 months.
- All clinical data on rinzimetostat are company-reported results of the phase 1/1b ORIC-944-01 study, released in press releases, investor presentations, and SEC filings; no peer-reviewed publication or congress abstract of rinzimetostat clinical results was identified. In the darolutamide dose-optimization cohort receiving 400 mg after abiraterone (18 participants), ORIC reported landmark rPFS rates of 93%, 84%, and 84% at 3, 4, and 5 months as of March 6, 2026, with a median follow-up of 4.9 months and median rPFS “Not mature”; confirmed PSA50 response in 5 of 15 participants (33%) at the January 16, 2026 cutoff; and MR50 in 10 of 14 participants (71%) with detectable baseline ctDNA. These are single-arm results without a concurrent control.
- In the same 400 mg cohort, ORIC reported fatigue in 39%, diarrhea in 22%, and nausea in 22% of participants, a single grade 3 treatment-related adverse event (6%), no serious treatment-related adverse events, and discontinuations in 6%. One grade 4 acute kidney injury was reported in the wider post-ARPI safety set of 72 participants. ORIC selected 400 mg once daily with darolutamide 600 mg twice daily as the recommended phase 3 dose after an exposure-response analysis of 113 participants.
- Himalayas-1 (NCT07723248) is a randomized, open-label phase 3 trial of approximately 600 participants comparing rinzimetostat plus darolutamide with physician’s choice of darolutamide, enzalutamide, or docetaxel. Its primary endpoint is rPFS by BICR, overall survival is the key secondary endpoint, and the registry lists an estimated primary completion in March 2028. No results have been released.
- Darolutamide, the partner drug, is labeled for nmCRPC and mCSPC; mCRPC is not a labeled indication. Its wholesale acquisition cost is $15,100.80 per 120-tablet bottle, effective 1 January 2026.
- Mevrometostat, an EZH2 inhibitor, is in a phase 3 trial (MEVPRO-1) in the same post-abiraterone population with the same primary endpoint; in a randomized phase 1 expansion it was associated with a median rPFS of 14.3 months with enzalutamide compared with 6.2 months with enzalutamide alone (hazard ratio 0.51). Tazemetostat was withdrawn from the U.S. market for hematologic second primary malignancies (18 of 318 participants, 5.7%). Comparisons of these agents with rinzimetostat are cross-trial.
- Evidence gaps for a formulary review are the absence of randomized results, overall survival data, health-related quality of life data, peer-reviewed rinzimetostat data, a price, and any budget impact or cost-effectiveness analysis of rinzimetostat.

Source: [ORIC Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526330631/oric-20260630.htm); [National Cancer Institute Thesaurus](https://api-evsrest.nci.nih.gov/api/v1/concept/ncit/C188381?include=full); [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/); [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm); [Swami et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42235146/); [Raval et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40670254/); [ClinicalTrials.gov NCT07723248](https://clinicaltrials.gov/study/NCT07723248); [Mateo et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Himalayas-1-TiP-Poster.pdf); [Nubeqa prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212099s016lbl.pdf); [California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026)](https://data.chhs.ca.gov/api/3/action/datastore_search_sql?sql=SELECT%20%22manufacturer_name%22%2C%22ndc%22%2C%22drug_prod_desc%22%2C%22wac_effective_date%22%2C%22wac_increase_amount%22%2C%22wac_after_increase%22%20FROM%20%22dda8a083-bc81-4f6d-b02f-935a2df70328%22%20WHERE%20%22drug_prod_desc%22%20LIKE%20%27Nubeqa%25%27); [Shore et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13203012/); [Schweizer et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.LBA138); [FDA Tazverik safety alert (2026)](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-alerts-health-care-providers-and-patients-about-increased-risk-new-blood-cancers-tazverik)

## Related pages
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
